BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Alere Inc. Acquires Additional Shares of Axis-Shield PLC


9/30/2011 10:48:49 AM

WALTHAM, Mass., Sept. 30, 2011 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that on September 29, 2011, it has purchased an additional 5,443,771 shares of Axis-Shield stock, bringing its total current ownership position to 10,990,468 shares, or approximately 21.98%, of Axis-Shield's issued and outstanding ordinary share capital. The additional shares were purchased at a price per share of 460 pence. On August 5, Alere announced an offer to acquire all of the issued and to be issued share capital of Axis-Shield, whose shares are traded on the main market of the London Stock Exchange and on the Oslo Bors, for 460 pence per share.

The complete announcement of the additional open market purchases was made through the Regulatory News Service of the London Stock Exchange pursuant to UK regulatory and legal requirements. A copy of the regulatory announcement can be found on the Alere website, http://www.alere.com, and the website of the London Stock Exchange, www.londonstockexchange.com.

The offer is for the securities of a corporation organized under the laws of Scotland and is subject to the procedure and disclosure requirements of the United Kingdom, including the City Code on Takeovers and Mergers (the "Code"), which are different from those of the United States. The offer is made in the United States pursuant to Section 14(e) of the US Securities Exchange of 1934, as amended (the "Exchange Act"), subject to the exemptions provided by Rule 14d-1(c) under the Exchange Act and otherwise in accordance with the requirements of the Code. Accordingly, the offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, the offer timetable, settlement procedures and timing of payments that are different from those applicable under US domestic tender offer procedures and laws.

About Alere

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts.

SOURCE Alere Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->